Diligence memo · auto-generated · as of July 2, 2026
CardioVascular BioTherapeutics, Inc.
CardioVascular BioTherapeutics, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
CardioVascular BioTherapeutics, Inc. operates in Biotechnology, based in LAS VEGAS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
CardioVascular BioTherapeutics, Inc. has raised $49M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $49M on —.
Valuation (modeled)modeled
Provath models CardioVascular BioTherapeutics, Inc. at approximately $204M (range $152M–$235M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.18× the median modeled value of Series C Biotechnology companies (394 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
No dated round to assess.
Comparablesmixed
Capital scale ranks ahead of 81% of Biotechnology peers (4293 compared).
Modeled value ranks above 72% of those peers.
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.